Table 3.
The Meta-analysis of clinicopathological characteristics between patients with CLDN18-ARHGAP fusion positive and negative patients.
| Characteristics | Included Study |
CLDN18-ARHGAP Fusion (+) N = (%) |
CLDN18-ARHGAP fusion (–) N= (%) |
Test of Heterogeneity | Meta-analysis | ||||
|---|---|---|---|---|---|---|---|---|---|
| χ2 | I2 (%) | p-value | OR or MD | 95% CI | p-value | ||||
| Age (years) | (4, 6, 8) | 112 | 1177 | 8.76 | 77 | 0.01 | −5.85 | −11.22 to −0.48 | 0.03 |
| Gender (Male) | (4, 6–9) | 61/151 (40.4) | 1,107/1,668 (66.4) | 8.51 | 53 | 0.07 | 0.40 | 0.23–0.70 | 0.001 |
| Tumor Location (Upper) | (4, 6–9) | 31/151 (20.5) | 621/1,668 (37.2) | 14.19 | 72 | 0.007 | 0.68 | 0.27–1.75 | 0.43 |
| T stage (T2–T4) | (4, 6–8) | 116/134 (86.6) | 1,131/1,301 (86.9) | 0.63 | 0 | 0.89 | 1.76 | 0.96–3.22 | 0.07 |
| N stage (N+) | (4, 6–8) | 110/134 (82.1) | 902/1,301 (69.3) | 3.33 | 10 | 0.34 | 3.41 | 2.00–5.82 | <0.001 |
| TNM stage (III–IV) | (4, 6, 7, 9) | 120/151 (79.5) | 1,046/1,668 (62.7) | 7.66 | 48 | 0.10 | 3.07 | 1.56–6.05 | <0.001 |
95% CI, 95% confidence interval; MD, mean difference; OR, odds ratio.